{"id":"pediacel-and-prevenar","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site pain"},{"rate":"5-10%","effect":"Fever"},{"rate":"5-10%","effect":"Irritability"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1628401","moleculeType":"Small molecule","molecularWeight":"657.81"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PEDIACEL and Prevenar contain inactivated antigens from diphtheria, tetanus, pertussis, and pneumococcal bacteria, as well as hepatitis B surface antigen. These antigens are combined with adjuvants to enhance the immune response. The immune system recognizes the antigens as foreign and mounts an immune response, producing antibodies that can neutralize or remove the pathogens from the body.","oneSentence":"PEDIACEL and Prevenar stimulate the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and 13 serotypes of pneumococcal disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:01.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Protection against diphtheria, tetanus, pertussis, hepatitis B, and 13 serotypes of pneumococcal disease in infants and young children"},{"name":"Prevention of invasive pneumococcal disease in infants and young children"}]},"trialDetails":[{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT01411241","phase":"PHASE3","title":"Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-07-18","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":720},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT00343421","phase":"PHASE3","title":"Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":588},{"nctId":"NCT00355654","phase":"PHASE3","title":"Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Infant, Healthy","enrollment":847}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PEDIACEL®: DT5aP-IPV-Hib 5-component Pertussis vaccine","Prevenar®: Pneumococcal saccharide conj. vaccine, adsorbed"],"phase":"phase_3","status":"active","brandName":"PEDIACEL® and Prevenar®","genericName":"PEDIACEL® and Prevenar®","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"PEDIACEL and Prevenar stimulate the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and 13 serotypes of pneumococcal disease. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, and 13 serotypes of pneumococcal disease in infants and young children, Prevention of invasive pneumococcal disease in infants and young children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}